The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
06-May-24
Pending
Undisclosed
Target:
Veen Bosch & Keuning
Acquiror:
Simon & Schuster
Advising Veen Bosch & Keuning, the largest book publisher in the Netherlands, on its sale to Simon & Schuster, one of the world’s preeminent publishing houses
13-Mar-24
$590 million (AUD value)
Target:
Liontown Resources Limited
Advised Australian-based lithium company Liontown Resources Limited on its A$590m debt facility to fund the Kathleen Valley Lithium Project
20-Feb-24
Pending
$185 million
Target:
myHomecare Group
Acquiror:
Australian Unity
Advising Australian Unity on its acquisition of myHomecare Group
13-Dec-23
Pending
Undisclosed
Target:
Vopak Moda Houston
Acquiror:
Exolum
Advising Exolum on its acquisition of 50% interest in Vopak Moda Houston, a leading ammonia and NGL storage & export terminal, from Moda Midstream (Encap Flatrock-Backed)
26-Oct-23
~$755 million
Target:
Innergex France
Acquiror:
Crédit Agricole Assurances
Advised Crédit Agricole Assurances, France’s largest insurance Group, in relation to its long-term partnership agreement with Innergex Renewable Energy Inc. (TSX: INE) and the acquisition of a 30% minority stake in Innergex France, the French operating and development activities of Innergex Renewable Energy Inc, for an enterprise value of €715m (@ 100%)
19-Oct-23
$390 million (AUD value)
Target:
Liontown Resources Limited
Advised Australian-based lithium company Liontown Resources Limited on its A$390m equity raising to fund the Kathleen Valley Lithium Project
04-Sep-23
Pending
$6.6 billion AUD
Target:
Liontown Resources Limited
Acquiror:
Albemarle Corporation
Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
08-Aug-23
Pending
Undisclosed
Target:
Farmalider Group
Acquiror:
MCH
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
21-Jul-23
Undisclosed
Target:
Synfonium / Qwant / Shadow
Acquiror:
Caisse des Dépôts et Consignations (CDC) / Banque des Territoires
Advised Banque des Territoires / Groupe Caisse des Dépôts (CDC), a French Public Institution, on the investment in the newly created platform Synfonium, incorporating Shadow, a cloud-based platform, and Qwant, a sovereign search engine. CDC will hold a 25% stake in Synfonium, while Octave Klaba and Miroslaw Klaba, the co-founders of OVHcloud, will hold the remaining 75%
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
29-Mar-23
Undisclosed
Target:
Scandinavian Enviro Systems AB
Acquiror:
Antin Infrastructure Partners
Advising Enviro on the creation of the world’s first large-scale tire recycling group in a JV with Antin Infrastructure Partners, supported by Michelin
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
28-Dec-22
Pending
Undisclosed
Target:
Eisai Distribution Co., Ltd.
Acquiror:
Yasuda Logistics Corporation
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
23-Dec-22
Pending
Undisclosed
Target:
Exyte Management GmbH
Acquiror:
BDT Capital Partners LLC
Advising Stumpf Capital and Georg Stumpf on the sale of a minority interest in its wholly-owned company, Exyte, a global leader in the design, engineering and delivery of high-tech facilities, to funds affiliated with BDT Capital Partners
16-Dec-22
Pending
$617 million
Target:
Asterion Energies
Acquiror:
Repsol
Advising Asterion Industrial Partners, a leading independent investment management firm, on the sale of their portfolio company Asterion Energies, a leading Pan-European renewable energy platform with over 7.7 GW of Solar PV and Wind assets in Spain, Italy and France
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
18-Nov-22
Pending
$6.4 billion
Target:
OZ Minerals Limited
Acquiror:
BHP Group Limited
Advising Australian-based copper company OZ Minerals Limited, on its response to two change of control proposals from BHP Group Limited, the world’s largest diversified resources company
27-Oct-22
$950 million
Target:
Minnesota Rubber and Plastics
Acquiror:
Trelleborg
Facilitated the sale of KKR’s portfolio company Minnesota Rubber and Plastics, a leading provider of materials science-based elastomer and thermoplastic solutions, to Trelleborg
05-Oct-22
Undisclosed
Target:
Precision Surfacing Solutions
Acquiror:
Bison Capital and Angeles Equity
Advised Precision Surfacing Solutions, a leading manufacturer of precision surface finishing equipment and related aftermarket parts and services, on its sale to Bison Capital and Angeles Equity
13-Sep-22
Undisclosed
Target:
InterGen N.V.’s UK business
Acquiror:
Bortela Capital s.r.o
Advised InterGen N.V., one of the UK’s largest independent power producers with a portfolio of four gas plants and a pipeline of large-scale battery energy storage system projects, on the sale of its business interests in the UK to CREDITAS Group, a Czech entity ultimately owned by Pavel Hubáček, whose energy division UCED is the fourth largest energy distributor in the Czech Republic
02-Sep-22
Pending
$205 million
Target:
brsk
Acquiror:
Ares Management
Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager